Homology Medicines Dividends and Buybacks
Dividend criteria checks 0/6
Homology Medicines does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.3%
Buyback Yield
| Total Shareholder Yield | -0.3% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely
Nov 16
Homology Medicines appoints new CEO, chairperson
Sep 06Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid
Jul 05Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
Jan 28Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
Oct 22We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth
Sep 18Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%
Aug 14Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts
May 22Homology Medicines (FIXX) Investor Presentation - Slideshow
May 05Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
Apr 17Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?
Mar 13Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year
Feb 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if FIXX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FIXX's dividend payments have been increasing.
Dividend Yield vs Market
| Homology Medicines Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (FIXX) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (FIXX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate FIXX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FIXX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FIXX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FIXX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/26 07:13 |
| End of Day Share Price | 2024/03/25 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Homology Medicines, Inc. is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Jason Zemansky | BofA Global Research |
| Madhu Kumar | B. Riley Securities, Inc. |